ATE311179T1 - Verwendungen und zusammensetzungen zur behandlung von primären und sekundären tumoren des zentralnervensystems (zns) - Google Patents

Verwendungen und zusammensetzungen zur behandlung von primären und sekundären tumoren des zentralnervensystems (zns)

Info

Publication number
ATE311179T1
ATE311179T1 AT00304737T AT00304737T ATE311179T1 AT E311179 T1 ATE311179 T1 AT E311179T1 AT 00304737 T AT00304737 T AT 00304737T AT 00304737 T AT00304737 T AT 00304737T AT E311179 T1 ATE311179 T1 AT E311179T1
Authority
AT
Austria
Prior art keywords
nervous system
central nervous
cns
compositions
secondary tumors
Prior art date
Application number
AT00304737T
Other languages
English (en)
Inventor
Rudiger Stendel
Rolf Wilhelm Pfirrmann
Original Assignee
Geistlich Soehne Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27538049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE311179(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Geistlich Soehne Ag filed Critical Geistlich Soehne Ag
Application granted granted Critical
Publication of ATE311179T1 publication Critical patent/ATE311179T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
AT00304737T 1999-06-04 2000-06-05 Verwendungen und zusammensetzungen zur behandlung von primären und sekundären tumoren des zentralnervensystems (zns) ATE311179T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13742199P 1999-06-04 1999-06-04
US15105099P 1999-08-27 1999-08-27
US16768199P 1999-11-29 1999-11-29
US17460700P 2000-01-05 2000-01-05
US18220000P 2000-02-14 2000-02-14

Publications (1)

Publication Number Publication Date
ATE311179T1 true ATE311179T1 (de) 2005-12-15

Family

ID=27538049

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00304737T ATE311179T1 (de) 1999-06-04 2000-06-05 Verwendungen und zusammensetzungen zur behandlung von primären und sekundären tumoren des zentralnervensystems (zns)

Country Status (7)

Country Link
US (4) US6479481B1 (de)
EP (2) EP1066830B1 (de)
JP (2) JP2001010976A (de)
AT (1) ATE311179T1 (de)
CA (1) CA2310534C (de)
DE (1) DE60024360T2 (de)
ES (2) ES2251939T3 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070275955A1 (en) * 1997-07-31 2007-11-29 Ed. Geistlich Soehne Ag Method of treating tumors
US7151099B2 (en) 1998-07-31 2006-12-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US8304390B2 (en) * 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US6479481B1 (en) 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
US20060199811A1 (en) * 1997-07-31 2006-09-07 Pfirrmann Rolf W Method of treatment for preventing or reducing tumor growth in the liver of patient
US6821968B2 (en) * 2001-09-26 2004-11-23 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Stable taurolidine electrolyte solutions
US7345039B2 (en) * 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US7892530B2 (en) * 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US20030225067A1 (en) * 1999-06-04 2003-12-04 Ruediger Stendel Microdialysis methods and applications for treatment and/or prophylaxis of tumors and/or infections in the central nervous system (CNS) and/or in other parenchymal organs
US20020098164A1 (en) 2000-10-27 2002-07-25 Redmond H. Paul Treatment of tumor metastases and cancer
US8030301B2 (en) * 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US20050096314A1 (en) * 2001-04-03 2005-05-05 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
CA2393252A1 (en) 1999-12-06 2001-06-07 Paul Calabresi Use of methylol-containing compounds to treat tumors
CN100519525C (zh) * 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
EP1797884B1 (de) * 1999-12-06 2013-09-11 Geistlich Pharma AG Taurolidin oder Taurultam zur Verwendung bei der Behandlung von Tumoren der Prostata, des Kolons, der Lungen und von wiederkehrendem Glioblastoma multiforme.
CA2363973C (en) * 2000-11-28 2009-03-10 Ed. Geistlich Sohne Ag Fur Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US6812251B2 (en) * 2001-03-15 2004-11-02 Rhode Island Hospital Taurine compounds
CA2462564C (en) 2001-10-01 2012-07-10 Rhode Island Hospital Methods of inhibiting metastases
JP2003119136A (ja) * 2001-10-10 2003-04-23 Mutsuyuki Kochi 悪性細胞の分化誘導剤組成物とその使用
JP5346148B2 (ja) * 2003-03-28 2013-11-20 エー・デー・ガイストリヒ・ゾーネ・アクチェンゲゼルシャフト・フュール・ヒェーミシェ・インダストリー 抗新生物性組成物および治療方法
US8236794B2 (en) 2003-09-29 2012-08-07 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
US20080177217A1 (en) * 2004-05-14 2008-07-24 Hans-Dietrich Polaschegg Taurolidine Formulations and Delivery: Therapeutic Treatments and Antimicrobial Protection Against Bacterial Biofilm Formation
US20070032453A1 (en) * 2005-08-04 2007-02-08 Oklahoma Medical Research Foundation Adjuvant chemotherapy for anaplastic gliomas
EP3028705A1 (de) * 2006-09-07 2016-06-08 Ed. Geistlich Söhne Ag Für Chemische Industrie Behandlung von knochenkrebs
US20190381060A1 (en) * 2016-01-11 2019-12-19 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
JP2019505586A (ja) * 2016-01-11 2019-02-28 コーメディクス・インコーポレーテッド 神経芽細胞腫及びその他のがん治療のための治療ナノ粒子
US11541061B2 (en) 2016-01-11 2023-01-03 Cormedix Inc. Neuroblastoma treatment with taurolidine hydrolysis products
CN105943522B (zh) * 2016-05-19 2019-06-21 中国医学科学院基础医学研究所 氯福克酚用于制备治疗人神经胶质瘤的药物的用途
KR101880015B1 (ko) * 2017-12-08 2018-07-19 아주대학교산학협력단 인터페론 감마를 유효성분으로 함유하는 신경섬유육종 예방 또는 치료용 조성물
US11738120B1 (en) 2022-04-14 2023-08-29 Cormedix Inc. Synthesis of taurolidine, purity profiles and polymorphs

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8328111D0 (en) 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compounds
US5210083A (en) * 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
GB8617482D0 (en) 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
GB9005856D0 (en) * 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
GB9015108D0 (en) 1990-07-09 1990-08-29 Geistlich Soehne Ag Chemical compositions
CA2098198A1 (en) * 1990-12-18 1992-06-18 Ann Christie King Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
JP3580867B2 (ja) * 1994-09-07 2004-10-27 株式会社東芝 医療用ゾンデ
GB9600426D0 (en) 1996-01-10 1996-03-13 Ed Geistlich Sohne A G Compositions
CA2289837A1 (en) * 1997-05-15 1998-11-19 Michael E. Moseley Method and apparatus for targeted drug delivery into a living patient using magnetic resonance imaging
US6479481B1 (en) 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
GB9716219D0 (en) * 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
CA2302720C (en) 1999-03-29 2009-07-14 Ed Geistlich Sohne Ag Fur Chemische Industrie Anticoagulant/sterilizing compositions and methods
US20020098164A1 (en) * 2000-10-27 2002-07-25 Redmond H. Paul Treatment of tumor metastases and cancer
CA2393252A1 (en) * 1999-12-06 2001-06-07 Paul Calabresi Use of methylol-containing compounds to treat tumors

Also Published As

Publication number Publication date
ES2532259T3 (es) 2015-03-25
US20030195198A1 (en) 2003-10-16
US7638511B2 (en) 2009-12-29
CA2310534A1 (en) 2000-12-04
ES2251939T3 (es) 2006-05-16
CA2310534C (en) 2011-01-18
US8202860B2 (en) 2012-06-19
EP1595543A3 (de) 2006-08-02
JP2008195726A (ja) 2008-08-28
US20030064942A1 (en) 2003-04-03
US6815441B2 (en) 2004-11-09
US20100048542A1 (en) 2010-02-25
EP1066830B1 (de) 2005-11-30
EP1595543A2 (de) 2005-11-16
EP1595543B1 (de) 2014-12-17
DE60024360T2 (de) 2006-06-08
US6479481B1 (en) 2002-11-12
DE60024360D1 (de) 2006-01-05
EP1066830A2 (de) 2001-01-10
JP2001010976A (ja) 2001-01-16
EP1066830A3 (de) 2002-10-16

Similar Documents

Publication Publication Date Title
ATE311179T1 (de) Verwendungen und zusammensetzungen zur behandlung von primären und sekundären tumoren des zentralnervensystems (zns)
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
BR9811482A (pt) Derivados de 1-(n-fenilaminoalquil)-piperazina substituìda na posição 2 do anel fenìlico
DE69829412D1 (de) Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
ATE412642T1 (de) Inhibitoren von p-38-kinase
HK1026691A1 (en) Substituted benzimidazoles and their use for treating retroviral infection
NZ234327A (en) Quinazoline derivatives and pharmaceutical compositions
MX9700557A (es) Dihidrobenzofuranos.
HUT67742A (en) Phosphono-oxymethyl-ethers of taxane derivatives
DE69716925D1 (de) Isoxazoline derivate und ihre verwendung als antimikroben
ATE253063T1 (de) 5-ht1f-agonisten
DE60027913D1 (de) 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz
ATE277072T1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
ATE251624T1 (de) Granulatimide-derivate zur behandlung von krebs
MXPA02009549A (es) Imidazopiridinas triciclicas.
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
ATE148109T1 (de) Hiv-proteaseinhibitoren und ihre verwendung zur behandlung von aids
NO20002408D0 (no) 5-HT1F antagonister
DE60126225D1 (de) Zusammensetzung zur Behandlung von Tumoren oder Krebs, welche Fluorouracil und ein Methylol Übertragungsmittel enthält
ATE267018T1 (de) Verwendung von peptidverbindungen zur behandlung von sle
BR9714408A (pt) Heterocicliluracilas
ATE218138T1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung
ES2135383T3 (es) Pirido(3,4-b)pirrolo(1,2-e)(1,4,5)oxadiazepinas y compuestos analogos relacionados, un procedimiento para su preparacion y su uso como medicamentos.
BG105549A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
ES2072334T3 (es) Derivados de 4,5,5a,6-tetrahidro-3h-isoxazolo(5,4,3-kl)acridinas, un procedimiento para su preparacion y su uso como medicamentos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1066830

Country of ref document: EP